Biocomposites was granted an expanded approval in India for STIMULAN Rapid Cure. The approval from India’s Central Drugs Standard Control Organisation allows STIMULAN Rapid Cure to be mixed with a wider variety of antibiotics than before, including in combination, and also with antifungals, to assist in wound healing and treatment of infection.
STIMULAN Rapid Cure is already the only calcium matrix approved to be mixed with an antibiotic for use in bone and surrounding soft tissue, having received that authorisation in more than 60 countries worldwide. India has now become the first country in the world to approve STIMULAN Rapid Cure to be mixed with antifungals, expanding the options available to surgeons when deciding on treatment strategies for their patients.
Michael Harris, Chief Executive Officer of Biocomposites, said: “This expanded approval for STIMULAN Rapid Cure will allow surgeons in India to tailor antimicrobial treatment strategies to their patients’ needs. STIMULAN Rapid Cure already helps more than 150,000 patients worldwide every year, and is an important tool for surgeons as they tackle the impact of antimicrobial resistance and help their patients.”
Biocomposites was granted an expanded approval in India for STIMULAN Rapid Cure. The approval from India's Central Drugs Standard Control Organisation allows STIMULAN Rapid Cure to be mixed with a wider variety of antibiotics than before, including in combination, and also with antifungals, to assist in wound healing and treatment of...
Biocomposites was granted an expanded approval in India for STIMULAN Rapid Cure. The approval from India’s Central Drugs Standard Control Organisation allows STIMULAN Rapid Cure to be mixed with a wider variety of antibiotics than before, including in combination, and also with antifungals, to assist in wound healing and treatment of infection.
STIMULAN Rapid Cure is already the only calcium matrix approved to be mixed with an antibiotic for use in bone and surrounding soft tissue, having received that authorisation in more than 60 countries worldwide. India has now become the first country in the world to approve STIMULAN Rapid Cure to be mixed with antifungals, expanding the options available to surgeons when deciding on treatment strategies for their patients.
Michael Harris, Chief Executive Officer of Biocomposites, said: “This expanded approval for STIMULAN Rapid Cure will allow surgeons in India to tailor antimicrobial treatment strategies to their patients’ needs. STIMULAN Rapid Cure already helps more than 150,000 patients worldwide every year, and is an important tool for surgeons as they tackle the impact of antimicrobial resistance and help their patients.”
Copy to clipboard 
